Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Paassen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nature Medicine|January 6, 2026
Going beyond genomics in precision oncologyIrene Paassen, Mark A Rubin
Frontiers in Cell and Developmental Biology|March 15, 2021
<i>In vitro</i> Modeling of Embryonal TumorsLars Custers, Irene Paassen, Jarno Drost
Nature Communications|December 1, 2023
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumorsNing Qing Liu, Irene Paassen, Lars Custers, et al.
International Journal of Molecular Sciences|September 9, 2023
CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in <i>KMT2A</i>-Rearranged Acute Lymphoblastic LeukemiaPauline Schneider, Priscilla Wander, Susan T C J M Arentsen-Peters, et al.
Oncogene|April 5, 2023
Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilitiesIrene Paassen, Justin Williams, Carla Ríos Arceo, et al.
Cell Reports|August 25, 2021
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumorsCamilla Calandrini, Sander R van Hooff, Irene Paassen, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader moleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Neuro-Oncology|July 29, 2025
A cycling, progenitor-like cell population at the base of atypical teratoid rhabdoid tumor subtype differentiation trajectoriesEnrique Blanco-Carmona, Irene Paassen, Jiayou He, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nature Medicine|January 6, 2026
Going beyond genomics in precision oncologyIrene Paassen, Mark A Rubin
Frontiers in Cell and Developmental Biology|March 15, 2021
<i>In vitro</i> Modeling of Embryonal TumorsLars Custers, Irene Paassen, Jarno Drost
Nature Communications|December 1, 2023
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumorsNing Qing Liu, Irene Paassen, Lars Custers, et al.
International Journal of Molecular Sciences|September 9, 2023
CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in <i>KMT2A</i>-Rearranged Acute Lymphoblastic LeukemiaPauline Schneider, Priscilla Wander, Susan T C J M Arentsen-Peters, et al.
Oncogene|April 5, 2023
Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilitiesIrene Paassen, Justin Williams, Carla Ríos Arceo, et al.
Cell Reports|August 25, 2021
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumorsCamilla Calandrini, Sander R van Hooff, Irene Paassen, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader moleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Neuro-Oncology|July 29, 2025
A cycling, progenitor-like cell population at the base of atypical teratoid rhabdoid tumor subtype differentiation trajectoriesEnrique Blanco-Carmona, Irene Paassen, Jiayou He, et al.
Pageof 1